Attovia director reports 72,792-share stock option

Attovia Therapeutics, Inc. reported the initial equity holdings of director John W. Smither.

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. reported the initial equity holdings of director John W. Smither. He holds a stock option to purchase 72,792 shares of common stock at an exercise price of $9.29 per share, expiring on July 1, 2036. The option vests over three years, with 33% vesting on July 2, 2027, an additional 33% on July 2, 2028, and the final 33% on July 2, 2029, subject to Mr. Smither’s continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Smither John W

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 72,792 contracts (Direct)

Footnotes (1)

1. F1. The option vests over a three-year period, with 33% vesting on July 2, 2027, an additional 33% on July 2, 2028 and the final 33% on July 2, 2029, subject to continued service to the Issuer through each vesting date.

Key Figures

Underlying shares: 72,792 shares Exercise price: $9.29 per share Option expiration: July 1, 2036 +3 more

6 metrics

Underlying shares 72,792 shares Common stock underlying reported stock option holding

Exercise price $9.29 per share Exercise price of stock option (Right to Buy)

Option expiration July 1, 2036 Expiration date of the reported stock option

First vesting tranche 33% on July 2, 2027 Initial vesting installment subject to continued service

Second vesting tranche 33% on July 2, 2028 Second vesting installment subject to continued service

Final vesting tranche 33% on July 2, 2029 Final vesting installment subject to continued service

Key Terms

Stock Option (Right to Buy), underlying security, vesting

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

underlying security financial

"underlying_security_title: Common Stock as the underlying security"

vesting financial

"The option vests over a three-year period, with 33% vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Attovia Therapeutics (ATTO) disclose about John W. Smither in this Form 3?

The filing shows director John W. Smither holds a stock option over 72,792 common shares at an exercise price of $9.29 per share, expiring July 1, 2036, as his reported equity position.

How many Attovia Therapeutics (ATTO) shares are covered by John W. Smither’s option?

John W. Smither’s reported stock option covers 72,792 shares of Attovia Therapeutics common stock. These are underlying shares subject to vesting conditions over a three-year schedule starting in 2027.

What is the exercise price of John W. Smither’s Attovia (ATTO) stock option?

The stock option held by John W. Smither has an exercise price of $9.29 per share. This is the price at which he may purchase each share, subject to vesting and the option’s July 1, 2036 expiration.

When does John W. Smither’s Attovia (ATTO) stock option expire?

The reported stock option expires on July 1, 2036. After this date, any unexercised portion of the 72,792-share option would lapse, assuming no earlier exercise and subject to plan terms.

What is the vesting schedule for John W. Smither’s Attovia (ATTO) option?

The option vests in three equal tranches of 33% each on July 2, 2027, July 2, 2028, and July 2, 2029. Vesting is conditioned on Mr. Smither’s continued service through each respective vesting date.

Does this Attovia (ATTO) Form 3 show any stock purchases or sales by John W. Smither?

The Form 3 reports a stock option holding but does not show any buy or sell transactions. It is an initial statement of beneficial ownership detailing his option-based equity position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 09:26 AM Accepted by SEC EDGAR 08/04/2026 - 07:28 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Smither John W

(Last) (First) (Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026

3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/01/2036	Common Stock	72,792	$9.29	D

Explanation of Responses:

1. The option vests over a three-year period, with 33% vesting on July 2, 2027, an additional 33% on July 2, 2028 and the final 33% on July 2, 2029, subject to continued service to the Issuer through each vesting date.

Remarks:

Exhibit Index Exhibit No. EX-24.1 Description Power of Attorney

	/s/ Steve Chan, Attorney-in-Fact	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)